Minireview

12-lipoxygenase and islet β-cell dysfunction in diabetes

Sarah A. Tersey, Esther Bolanis, Theodore R. Holman, David J. Maloney, Jerry L. Nadler, Raghu Mirmira

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

The insulin producing islet β-cells have increasingly gained attention for their role in the pathogeneses of virtually all forms of diabetes. Dysfunction, de-differentiation, and/or death of β-cells are pivotal features in the transition from normoglycemia to hyperglycemia in both animal models of metabolic disease and humans. In both type 1 and type 2 diabetes, inflammation appears to be a central cause of β-cell derangements, and molecular pathways that modulate inflammation or the inflammatory response are felt to be prime targets of future diabetes therapy. The lipoxygenases (LOs) represent a class of enzymes that oxygenate cellular polyunsaturated fatty acids to produce inflammatory lipid intermediates that directly and indirectly affect cellular function and survival. The enzyme 12-LO is expressed in all metabolically active tissues, including pancreatic islets, and has received increasing attention for its role in promoting cellular inflammation in the setting of diabetes. Genetic deletion models of 12-LO in mice reveal striking protection from metabolic disease and its complications and an emerging body of literature has implicated its role in human disease. This review focuses on the evidence supporting the proinflammatory role of 12-LO as it relates to islet β-cells, and the potential for 12-LO inhibition as a future avenue for the prevention and treatment of metabolic disease

Original languageEnglish
Pages (from-to)791-800
Number of pages10
JournalMolecular Endocrinology
Volume29
Issue number6
DOIs
StatePublished - Jun 1 2015

Fingerprint

Arachidonate 12-Lipoxygenase
Islets of Langerhans
Metabolic Diseases
Inflammation
Lipoxygenases
Genetic Models
Enzymes
Unsaturated Fatty Acids
Type 1 Diabetes Mellitus
Hyperglycemia
Type 2 Diabetes Mellitus
Cell Death
Animal Models
Insulin
Lipids
Survival

ASJC Scopus subject areas

  • Molecular Biology
  • Endocrinology

Cite this

Tersey, S. A., Bolanis, E., Holman, T. R., Maloney, D. J., Nadler, J. L., & Mirmira, R. (2015). Minireview: 12-lipoxygenase and islet β-cell dysfunction in diabetes. Molecular Endocrinology, 29(6), 791-800. https://doi.org/10.1210/me.2015-1041

Minireview : 12-lipoxygenase and islet β-cell dysfunction in diabetes. / Tersey, Sarah A.; Bolanis, Esther; Holman, Theodore R.; Maloney, David J.; Nadler, Jerry L.; Mirmira, Raghu.

In: Molecular Endocrinology, Vol. 29, No. 6, 01.06.2015, p. 791-800.

Research output: Contribution to journalArticle

Tersey, SA, Bolanis, E, Holman, TR, Maloney, DJ, Nadler, JL & Mirmira, R 2015, 'Minireview: 12-lipoxygenase and islet β-cell dysfunction in diabetes', Molecular Endocrinology, vol. 29, no. 6, pp. 791-800. https://doi.org/10.1210/me.2015-1041
Tersey, Sarah A. ; Bolanis, Esther ; Holman, Theodore R. ; Maloney, David J. ; Nadler, Jerry L. ; Mirmira, Raghu. / Minireview : 12-lipoxygenase and islet β-cell dysfunction in diabetes. In: Molecular Endocrinology. 2015 ; Vol. 29, No. 6. pp. 791-800.
@article{92c4b0322888471caf9aaae01d5ce410,
title = "Minireview: 12-lipoxygenase and islet β-cell dysfunction in diabetes",
abstract = "The insulin producing islet β-cells have increasingly gained attention for their role in the pathogeneses of virtually all forms of diabetes. Dysfunction, de-differentiation, and/or death of β-cells are pivotal features in the transition from normoglycemia to hyperglycemia in both animal models of metabolic disease and humans. In both type 1 and type 2 diabetes, inflammation appears to be a central cause of β-cell derangements, and molecular pathways that modulate inflammation or the inflammatory response are felt to be prime targets of future diabetes therapy. The lipoxygenases (LOs) represent a class of enzymes that oxygenate cellular polyunsaturated fatty acids to produce inflammatory lipid intermediates that directly and indirectly affect cellular function and survival. The enzyme 12-LO is expressed in all metabolically active tissues, including pancreatic islets, and has received increasing attention for its role in promoting cellular inflammation in the setting of diabetes. Genetic deletion models of 12-LO in mice reveal striking protection from metabolic disease and its complications and an emerging body of literature has implicated its role in human disease. This review focuses on the evidence supporting the proinflammatory role of 12-LO as it relates to islet β-cells, and the potential for 12-LO inhibition as a future avenue for the prevention and treatment of metabolic disease",
author = "Tersey, {Sarah A.} and Esther Bolanis and Holman, {Theodore R.} and Maloney, {David J.} and Nadler, {Jerry L.} and Raghu Mirmira",
year = "2015",
month = "6",
day = "1",
doi = "10.1210/me.2015-1041",
language = "English",
volume = "29",
pages = "791--800",
journal = "Molecular Endocrinology",
issn = "0888-8809",
publisher = "The Endocrine Society",
number = "6",

}

TY - JOUR

T1 - Minireview

T2 - 12-lipoxygenase and islet β-cell dysfunction in diabetes

AU - Tersey, Sarah A.

AU - Bolanis, Esther

AU - Holman, Theodore R.

AU - Maloney, David J.

AU - Nadler, Jerry L.

AU - Mirmira, Raghu

PY - 2015/6/1

Y1 - 2015/6/1

N2 - The insulin producing islet β-cells have increasingly gained attention for their role in the pathogeneses of virtually all forms of diabetes. Dysfunction, de-differentiation, and/or death of β-cells are pivotal features in the transition from normoglycemia to hyperglycemia in both animal models of metabolic disease and humans. In both type 1 and type 2 diabetes, inflammation appears to be a central cause of β-cell derangements, and molecular pathways that modulate inflammation or the inflammatory response are felt to be prime targets of future diabetes therapy. The lipoxygenases (LOs) represent a class of enzymes that oxygenate cellular polyunsaturated fatty acids to produce inflammatory lipid intermediates that directly and indirectly affect cellular function and survival. The enzyme 12-LO is expressed in all metabolically active tissues, including pancreatic islets, and has received increasing attention for its role in promoting cellular inflammation in the setting of diabetes. Genetic deletion models of 12-LO in mice reveal striking protection from metabolic disease and its complications and an emerging body of literature has implicated its role in human disease. This review focuses on the evidence supporting the proinflammatory role of 12-LO as it relates to islet β-cells, and the potential for 12-LO inhibition as a future avenue for the prevention and treatment of metabolic disease

AB - The insulin producing islet β-cells have increasingly gained attention for their role in the pathogeneses of virtually all forms of diabetes. Dysfunction, de-differentiation, and/or death of β-cells are pivotal features in the transition from normoglycemia to hyperglycemia in both animal models of metabolic disease and humans. In both type 1 and type 2 diabetes, inflammation appears to be a central cause of β-cell derangements, and molecular pathways that modulate inflammation or the inflammatory response are felt to be prime targets of future diabetes therapy. The lipoxygenases (LOs) represent a class of enzymes that oxygenate cellular polyunsaturated fatty acids to produce inflammatory lipid intermediates that directly and indirectly affect cellular function and survival. The enzyme 12-LO is expressed in all metabolically active tissues, including pancreatic islets, and has received increasing attention for its role in promoting cellular inflammation in the setting of diabetes. Genetic deletion models of 12-LO in mice reveal striking protection from metabolic disease and its complications and an emerging body of literature has implicated its role in human disease. This review focuses on the evidence supporting the proinflammatory role of 12-LO as it relates to islet β-cells, and the potential for 12-LO inhibition as a future avenue for the prevention and treatment of metabolic disease

UR - http://www.scopus.com/inward/record.url?scp=84930827504&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930827504&partnerID=8YFLogxK

U2 - 10.1210/me.2015-1041

DO - 10.1210/me.2015-1041

M3 - Article

VL - 29

SP - 791

EP - 800

JO - Molecular Endocrinology

JF - Molecular Endocrinology

SN - 0888-8809

IS - 6

ER -